false
Catalog
Making Sense of the Expanding Molecular Toolbox fo ...
Pigmented Lesions in the Molecular Era
Pigmented Lesions in the Molecular Era
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Alina Bridges discussed diagnostic and prognostic tests for pigmented lesions in dermatopathology, focusing on molecular testing. She highlighted the importance of molecular testing for assessing Spitz neoplasms, the historical significance of Sophie Spitz, and the evolving understanding of atypical Spitz neoplasms. Dr. Bridges emphasized the use of molecular tests, such as chromosomal microarray and next-generation sequencing, to differentiate between benign nevi and melanomas, including specific gene mutations associated with different types of melanocytic tumors.<br /><br />She also discussed the use of the CP-GEP Merlin assay for predicting nodal metastasis risk in melanoma patients eligible for sentinel lymph node biopsy, highlighting how the test can help determine whether patients should undergo the procedure or not based on their risk profile. Dr. Bridges explained the validation and reimbursement status of the test, as well as its potential future applications in liquid biopsies for monitoring disease progression and treatment responses in melanoma and Merkel cell carcinoma patients.
Asset Subtitle
Alina G. Bridges, DO, FAAD
Keywords
Dr. Alina Bridges
pigmented lesions
dermatopathology
molecular testing
Spitz neoplasms
Sophie Spitz
atypical Spitz neoplasms
chromosomal microarray
next-generation sequencing
CP-GEP Merlin assay
Legal notice
Copyright © 2025 American Academy of Dermatology. All rights reserved.
Reproduction or republication strictly prohibited without prior written permission.
×
Please select your language
1
English